Ignite Creation Date:
2025-12-24 @ 2:14 PM
Ignite Modification Date:
2026-04-15 @ 8:19 PM
Study NCT ID:
NCT01990495
Status:
COMPLETED
Last Update Posted:
2021-01-25
First Post:
2013-10-30
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Exercise to Prevent Muscle Mass and Functional Loss in Elderly Dialysis Patients
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D051436', 'term': 'Renal Insufficiency, Chronic'}, {'id': 'D051437', 'term': 'Renal Insufficiency'}], 'ancestors': [{'id': 'D007674', 'term': 'Kidney Diseases'}, {'id': 'D014570', 'term': 'Urologic Diseases'}, {'id': 'D052776', 'term': 'Female Urogenital Diseases'}, {'id': 'D005261', 'term': 'Female Urogenital Diseases and Pregnancy Complications'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D052801', 'term': 'Male Urogenital Diseases'}, {'id': 'D002908', 'term': 'Chronic Disease'}, {'id': 'D020969', 'term': 'Disease Attributes'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D015444', 'term': 'Exercise'}], 'ancestors': [{'id': 'D009043', 'term': 'Motor Activity'}, {'id': 'D009068', 'term': 'Movement'}, {'id': 'D009142', 'term': 'Musculoskeletal Physiological Phenomena'}, {'id': 'D055687', 'term': 'Musculoskeletal and Neural Physiological Phenomena'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'Drj993@aol.com', 'phone': '6504503440', 'title': 'Dr. Jonathan Myers', 'organization': 'VA Palo Alto Health Care System'}, 'certainAgreement': {'piSponsorEmployee': True}}, 'adverseEventsModule': {'timeFrame': '3 months', 'description': 'Subjects were monitored for any adverse events related to exercise testing, training, blood draws, and biopsy procedures. There were no adverse events during the study.', 'eventGroups': [{'id': 'EG000', 'title': 'Exercise', 'description': 'Subjects will participate in a center-based and home exercise training program for 3 months.', 'otherNumAtRisk': 13, 'deathsNumAtRisk': 13, 'otherNumAffected': 0, 'seriousNumAtRisk': 13, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'Usual Care', 'description': 'This group will be randomized to receive usual clinical care. No other interventions will be assigned to this group.', 'otherNumAtRisk': 15, 'deathsNumAtRisk': 15, 'otherNumAffected': 0, 'seriousNumAtRisk': 15, 'deathsNumAffected': 0, 'seriousNumAffected': 0}], 'frequencyThreshold': '1'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Maximal Oxygen Uptake', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '15', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Exercise', 'description': 'Subjects will participate in a center-based and home exercise training program for 3 months.'}, {'id': 'OG001', 'title': 'Usual Care', 'description': 'This group will be randomized to receive usual clinical care. No other interventions will be assigned to this group.'}], 'classes': [{'categories': [{'measurements': [{'value': '14.5', 'spread': '3.3', 'groupId': 'OG000'}, {'value': '15.1', 'spread': '3.3', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': '3 months', 'description': 'The overall primary outcome for the study is maximal oxygen uptake. Maximal oxygen uptake is the amount of oxygen consumed by the body during maximal exercise. It is the gold standard expression for exercise capacity.', 'unitOfMeasure': 'ml/kg/min', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Chronic kidney disease'}, {'type': 'SECONDARY', 'title': 'Biopsy of the Quadriceps Muscle.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '15', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Exercise', 'description': 'Subjects will participate in a hybrid, center-based and home exercise training program for 3 months.'}, {'id': 'OG001', 'title': 'Usual Care', 'description': 'This group will serve as control subjects. They will receive only usual clinical care.'}], 'classes': [{'categories': [{'measurements': [{'value': '33.2', 'spread': '11', 'groupId': 'OG000'}, {'value': '30.0', 'spread': '9', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': '3 Months', 'description': 'The biopsy procedures will permit the measurement of the percentage of type 1 fibers in the quadriceps muscle.\n\nThe biopsy procedures will also be used to quantify protein signaling, a measure of the capacity of the muscle to gain or lose muscle mass.', 'unitOfMeasure': 'Percentage of type 1 fibers', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Maintenance hemodialysis (\\>3 months)'}, {'type': 'SECONDARY', 'title': 'Quality of Life Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '15', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Exercise', 'description': 'Subjects will participate in a center-based and home exercise training program for 3 months.'}, {'id': 'OG001', 'title': 'Usual Care', 'description': 'This group will serve as control subjects. They will receive only usual clinical care.'}], 'classes': [{'categories': [{'measurements': [{'value': '48.7', 'spread': '25.6', 'groupId': 'OG000'}, {'value': '60.0', 'spread': '22.3', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': '3 months', 'description': 'Disease-specific quality of life instrument is used to quantify broad quality of life domains, including physical function.\n\nHigher scores mean better values using a 0-100 scale.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Chronic kidney disease on maintenance hemodialysis.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Exercise', 'description': 'The study involves two arms randomized to exercise and usual care groups\n\nExercise training: Subjects will participate in a center-based and home exercise training program for 3 months.\n\nUsual Care: This group will serve as control subjects. They will receive only usual clinical care.'}, {'id': 'FG001', 'title': 'Usual Care', 'description': 'This group will be randomized to receive usual clinical care. No other interventions will be assigned to this group.\n\nUsual Care: This group will serve as control subjects. They will receive only usual clinical care.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '18'}, {'groupId': 'FG001', 'numSubjects': '19'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '13'}, {'groupId': 'FG001', 'numSubjects': '15'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '5'}, {'groupId': 'FG001', 'numSubjects': '4'}]}], 'dropWithdraws': [{'type': 'Physician Decision', 'reasons': [{'groupId': 'FG000', 'numSubjects': '5'}, {'groupId': 'FG001', 'numSubjects': '4'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'BG000'}, {'value': '15', 'groupId': 'BG001'}, {'value': '28', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'Exercise', 'description': 'Subjects will participate in a center-based and home exercise training program for 3 months.'}, {'id': 'BG001', 'title': 'Usual Care', 'description': 'This group will be randomized to receive usual clinical care. No other interventions will be assigned to this group.'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Categorical', 'classes': [{'categories': [{'title': '<=18 years', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Between 18 and 65 years', 'measurements': [{'value': '3', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '5', 'groupId': 'BG002'}]}, {'title': '>=65 years', 'measurements': [{'value': '10', 'groupId': 'BG000'}, {'value': '13', 'groupId': 'BG001'}, {'value': '23', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '66.3', 'spread': '7.6', 'groupId': 'BG000'}, {'value': '66.2', 'spread': '6.7', 'groupId': 'BG001'}, {'value': '66.3', 'spread': '6.9', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Male', 'measurements': [{'value': '13', 'groupId': 'BG000'}, {'value': '15', 'groupId': 'BG001'}, {'value': '28', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Ethnicity (NIH/OMB)', 'classes': [{'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'value': '13', 'groupId': 'BG000'}, {'value': '15', 'groupId': 'BG001'}, {'value': '28', 'groupId': 'BG002'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Region of Enrollment', 'classes': [{'title': 'United States', 'categories': [{'measurements': [{'value': '13', 'groupId': 'BG000'}, {'value': '15', 'groupId': 'BG001'}, {'value': '28', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}], 'populationDescription': 'Chronic kidney disease on maintenance hemodialysis.'}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2020-05-31', 'size': 669942, 'label': 'Study Protocol and Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'Prot_SAP_000.pdf', 'typeAbbrev': 'Prot_SAP', 'uploadDate': '2021-01-01T16:19', 'hasProtocol': True}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 37}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2013-11-01', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2021-01', 'completionDateStruct': {'date': '2019-09-30', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2021-01-04', 'studyFirstSubmitDate': '2013-10-30', 'resultsFirstSubmitDate': '2020-12-03', 'studyFirstSubmitQcDate': '2013-11-14', 'lastUpdatePostDateStruct': {'date': '2021-01-25', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2021-01-04', 'studyFirstPostDateStruct': {'date': '2013-11-21', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2021-01-25', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2019-09-30', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Maximal Oxygen Uptake', 'timeFrame': '3 months', 'description': 'The overall primary outcome for the study is maximal oxygen uptake. Maximal oxygen uptake is the amount of oxygen consumed by the body during maximal exercise. It is the gold standard expression for exercise capacity.'}], 'secondaryOutcomes': [{'measure': 'Biopsy of the Quadriceps Muscle.', 'timeFrame': '3 Months', 'description': 'The biopsy procedures will permit the measurement of the percentage of type 1 fibers in the quadriceps muscle.\n\nThe biopsy procedures will also be used to quantify protein signaling, a measure of the capacity of the muscle to gain or lose muscle mass.'}, {'measure': 'Quality of Life Score', 'timeFrame': '3 months', 'description': 'Disease-specific quality of life instrument is used to quantify broad quality of life domains, including physical function.\n\nHigher scores mean better values using a 0-100 scale.'}]}, 'oversightModule': {'isUsExport': False, 'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Renal failure', 'Exercise testing', 'Exercise training', 'Protein signaling', 'Skeletal muscle'], 'conditions': ['Chronic Kidney Disease']}, 'referencesModule': {'references': [{'pmid': '35018639', 'type': 'DERIVED', 'citation': 'Bernier-Jean A, Beruni NA, Bondonno NP, Williams G, Teixeira-Pinto A, Craig JC, Wong G. Exercise training for adults undergoing maintenance dialysis. Cochrane Database Syst Rev. 2022 Jan 12;1(1):CD014653. doi: 10.1002/14651858.CD014653.'}, {'pmid': '33686542', 'type': 'DERIVED', 'citation': 'Myers J, Chan KN, Chen Y, Lit Y, Massaband P, Kiratli BJ, Tan JC, Rabkin R. Association of physical function and performance with peak VO2 in elderly patients with end stage kidney disease. Aging Clin Exp Res. 2021 Oct;33(10):2797-2806. doi: 10.1007/s40520-021-01801-6. Epub 2021 Mar 8.'}]}, 'descriptionModule': {'briefSummary': 'The majority of individuals with advanced ESRD have reduced exercise capacity in part due to decreased muscle mass. This leads to a reduced ability to perform daily activities, a greater incidence of falls, and a reduced quality of life. The mechanisms responsible for the loss of muscle mass in ESRD are not understood very well. This study is designed to determine the effectiveness of an exercise program on improving muscle mass, exercise capacity and quality of life in persons with ESRD. In addition, the study will attempt to better understand why muscle loss occurs in people with ESRD, the influence exercise has on these mechanisms, and whether the response to exercise can be enhanced with nutrient supplementation.', 'detailedDescription': 'Elderly patients comprising half the end-stage renal disease (ESRD) population, are especially vulnerable to loss of muscle mass, strength and function, changes that lead to frailty and increased morbidity and mortality. Many factors contribute to the decline in muscle mass and function in the elderly uremic and apart from aging and co-morbid conditions, wasting is worsened by inactivity. Studies in maintenance hemodialysis (MHD) patients have shown that exercise (EX), including endurance, resistance or combined, can counteract the loss of muscle mass and function. However most studies have not specifically targeted the elderly, involved small numbers or lacked controls and the impact on long-term outcome is unknown. Nevertheless, despite substantial evidence indicating that EX is beneficial and low cost, EX is not part of the routine care of MHD patients. In contrast EX is regarded as standard of care for the wasted elderly and also cardiac patients. Some protection against uremic muscle wasting can also be afforded by an adequate protein-calorie intake. Amino acids (AA) from this source serve as substrates for protein synthesis (PS) and also directly activate the mTOR signaling pathway stimulating PS. In normal subjects if AA are ingested at the time of resistance EX, anabolic signaling and PS is enhanced and this leads to increases in muscle mass. Whether the EX and AA stimulated signaling response is intact in elderly MHD patients is unknown and there is little information about the cellular processes invoked. Taking this all together, the investigators plan to test the hypothesis that a home-based EX program, effective in cardiac patients, will improve cardiopulmonary function and muscle mass and function in elderly MHD patients. Also, in a pilot study the investigators will examine whether a protein supplement acutely enhances EX stimulated anabolic signaling. Functionally impaired MHD subjects aged 65-80 yrs are randomized into 2 groups of 30 each, one undergoing EX and the other usual care. After 3 months, half in each group receive a one-time protein-calorie supplement or placebo during an acute bout of EX and muscle biopsied for examining the signaling response. Assays at baseline and at 3 months include cardiopulmonary function, muscle strength and function, body composition by DEXA, thigh muscle volume and composition by CT, quality of life (QOL) and cognitive function, and nutritional, inflammatory, lipid and biochemical status and morphologic and molecular analysis of biopsied muscle. The investigators anticipate that home-based EX will counteract muscle wasting, enhance cardiopulmonary and muscle function and QOL, and reduce surrogate markers of long-term outcome. New insights into the mechanisms whereby EX and nutrients induce an anabolic response in muscle of elderly uremics will be provided and may serve as a basis for devising strategies to counteract loss of muscle mass and function. Finally, the investigators anticipate that the EX program will be "user friendly" and may thus form a part of the routine care of elderly and perhaps younger MHD patients. If short-term benefits are evident from this study in elderly MHD patients, it could form the basis for a comprehensive long-term outcomes study.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '80 Years', 'minimumAge': '55 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Males and females aged 55-80 years undergoing maintenance hemodialysis (MHD) for at least three months and without other active/uncontrolled disease will be studied.\n* Exercise and usual care groups will be matched by age, body mass index (BMI), MHD duration, and protein intake using a stratified randomization approach.\n* Subjects will be required to be in the peak VO2 range of 10 to 20 ml/kg/min, equivalent to moderate functional impairment in patients with heart failure.\n* Subjects will be required to have dialysis treatment for \\>3 months with an average Kt/V 1.2, and be able to perform exercise safely.\n\nExclusion Criteria:\n\n* Current activity \\> 2 hrs/wk of moderate intensity exercise, temporary vascular access, uncontrolled diabetes mellitus, active vasculitis, active autoimmune disease, malignancy, severe obesity (BMI \\> 35), alcoholism or other recreational drug use, unstable cardiac disease (abnormal exercise test, angina, uncontrolled arrhythmias or myocardial infarction within three months), peripheral vascular disease (claudication with exercise), lung, liver or intestinal disease, those who are medically unstable and subjects who have received anabolic, catabolic or cytotoxic medications in the past 3 months.\n* The investigators will also exclude subjects with excessive previous exposure to radiation.'}, 'identificationModule': {'nctId': 'NCT01990495', 'acronym': 'PERFECT', 'briefTitle': 'Exercise to Prevent Muscle Mass and Functional Loss in Elderly Dialysis Patients', 'organization': {'class': 'FED', 'fullName': 'VA Office of Research and Development'}, 'officialTitle': 'Exercise to Prevent Muscle Mass and Functional Loss in Elderly Dialysis Patients', 'orgStudyIdInfo': {'id': 'E0915-R'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'ACTIVE_COMPARATOR', 'label': 'Exercise vs. usual care', 'description': 'The study involves two arms randomized to exercise and usual care groups', 'interventionNames': ['Other: Exercise training', 'Other: Usual Care']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Usual care', 'description': 'This group will be randomized to receive usual clinical care. No other interventions will be assigned to this group.', 'interventionNames': ['Other: Usual Care']}], 'interventions': [{'name': 'Exercise training', 'type': 'OTHER', 'description': 'Subjects will participate in a center-based and home exercise training program for 3 months.', 'armGroupLabels': ['Exercise vs. usual care']}, {'name': 'Usual Care', 'type': 'OTHER', 'description': 'This group will serve as control subjects. They will receive only usual clinical care.', 'armGroupLabels': ['Exercise vs. usual care', 'Usual care']}]}, 'contactsLocationsModule': {'locations': [{'zip': '94304-1290', 'city': 'Palo Alto', 'state': 'California', 'country': 'United States', 'facility': 'VA Palo Alto Health Care System, Palo Alto, CA', 'geoPoint': {'lat': 37.44188, 'lon': -122.14302}}], 'overallOfficials': [{'name': 'Jonathan Neil Myers, PhD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'VA Palo Alto Health Care System, Palo Alto, CA'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'VA Office of Research and Development', 'class': 'FED'}, 'responsibleParty': {'type': 'SPONSOR'}}}}